Esketamine for Postoperative Depression in Breast Cancer: fMRI Trial

SNIPPET: Intraoperative esketamine at 0.25 mg/kg significantly increases degree centrality of the left inferior frontal gyrus in breast cancer patients, correlating with reduced postoperative depressive symptoms. Baseline brain functional network measures may predict both short-term and long-term antidepressant response, according to a double-blind RCT published in Translational Psychiatry (Zhu et al., 2026).

The ProtoHuman Perspective#

Depression after breast cancer surgery isn't a footnote — it's a clinical variable that shapes recurrence risk, recovery trajectory, and mortality. Somewhere between 20% and 60% of breast cancer patients experience clinically significant depressive symptoms perioperatively, and the standard approach has been to deal with it after the fact. What makes this line of research genuinely interesting to me is the inversion of timing: intervene during surgery, not weeks later in a psychiatrist's office.

Esketamine — the S-enantiomer of ketamine — is already FDA-approved for treatment-resistant depression via nasal spray. But repurposing it as a perioperative psychiatric shield, and then using resting-state fMRI to predict who will respond, sits at an intersection of neuroscience, oncology, and precision medicine that I think deserves closer attention. The sample size gives me pause. But the mechanistic specificity — pinpointing the left inferior frontal gyrus opercular part — is the kind of finding that moves a field from "ketamine helps mood" to "here's where and how."

The Science#

Postoperative Depression in Breast Cancer: The Scale of the Problem#

Postoperative depression is not merely a psychological aftereffect. A systematic review by Pilevarzadeh et al. found global prevalence of depression among breast cancer patients ranges from 20% to 60%, depending on the screening tool and population studied ^[1]. Depression worsens surgical outcomes, increases complication rates, and — this is the part that should alarm people — is independently associated with higher recurrence and mortality risk ^[2].

The conventional response has been to screen and refer. But referral takes time, therapy takes longer, and SSRIs need weeks to reach efficacy. There's a temporal gap between the surgical insult and meaningful psychiatric intervention.

That's the gap esketamine is trying to fill.

The Zhu et al. Trial: Design and Key Findings#

Zhu et al. (2026) conducted a double-blind randomized controlled trial enrolling 35 breast cancer patients with preoperative depressive symptoms ^[3]. Patients received either intraoperative esketamine at 0.25 mg·kg⁻¹ (n = 18) or saline placebo (n = 17), infused over the first 40 minutes of anesthesia. Resting-state fMRI scans were acquired at baseline (preoperative) and postoperative day 1.

Here's where the graph theory analysis gets specific. The esketamine group — but not placebo — showed increased degree centrality of the left inferior frontal gyrus, opercular part (L-IFGoperc) from baseline to follow-up. Degree centrality, for those less familiar, measures how connected a brain region is to the rest of the network. Higher degree centrality means that node is talking to more of the brain.

This change correlated with improvement in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).

But here's where it gets complicated. The study also found that baseline network measures — at global, nodal, and edge levels — predicted both short-term (postoperative days 1–3) and long-term (postoperative week 12) improvement in MADRS scores. The brain regions implicated as predictors included the left precuneus, left putamen, left pallidum, left superior frontal gyrus (dorsolateral), right middle cingulate gyrus, and right supramarginal gyrus, among others ^[3].

I think the word "predictor" is doing a lot of heavy lifting in a sample of 35. Still, the specificity of these network-level associations — spanning subcortical structures involved in reward processing (putamen, pallidum) and cortical regions linked to self-referential thought (precuneus) and cognitive control (dorsolateral prefrontal areas) — maps onto what we know about depressive neurocircuitry in non-oncological contexts. The pattern holds, even if the evidence is early.

The Left Inferior Frontal Gyrus: Why This Region Matters#

The L-IFGoperc sits at the junction of language processing, emotional regulation, and cognitive reappraisal. It's part of the ventrolateral prefrontal cortex — a region consistently implicated in the effortful regulation of negative emotion. What does increased degree centrality here actually feel like? Probably something like improved capacity to reframe distress, to shift away from ruminative thought loops. I'm speculating, but it's grounded speculation.

Converging Evidence: The Broader Esketamine–Depression–Cancer Literature#

A separate, larger RCT by a different research group (published in BMC Psychiatry, February 2026) enrolled 120 breast cancer surgery patients and found that esketamine at induction (0.2 mg/kg) followed by maintenance infusion (0.1 mg/kg/h) produced significantly greater reductions in PHQ-9 depression scores at postoperative day 30 compared to placebo — adjusted mean difference of 0.96 points (95% CI 0.42–1.51, P < 0.01) ^[4]. Anxiety scores (SAS) also improved significantly at both day 7 and day 30.

Separately, Xu et al. (2025) identified a potential molecular mechanism: esketamine may alleviate postoperative depression by inhibiting TREK-1 two-pore domain potassium channels, enhancing GABA neurotransmitter release, and improving hippocampal neuronal activity ^[5]. This was demonstrated via transcriptomic sequencing of rat hippocampal neurons, so the usual caveats about translating rodent data to humans apply fully.

And in a parallel investigation of racemic ketamine for treatment-resistant depression, researchers found that a single subanesthetic dose (0.5 mg/kg) produced significant reductions in depressive, anhedonic, and ruminative symptoms at 24 hours — but, interestingly, symptom reduction correlated with pre-infusion resting-state functional connectivity, not with changes in connectivity post-infusion ^[6]. That's a subtle but important distinction: it suggests baseline brain state may determine who responds, not just what the drug does acutely.

Let me push back on that slightly. The Zhu et al. trial does show a change — increased L-IFGoperc centrality — that correlates with symptom improvement. So the picture is probably more nuanced than "baseline predicts everything." My honest read: both baseline architecture and acute network reorganization likely matter, and we're still figuring out the relative contribution of each.

Comparison Table#

The Protocol#

Important caveat: This protocol reflects what the current clinical trials have tested. Esketamine for perioperative depression in breast cancer is not yet standard of care. These steps are for clinicians and informed patients in consultation with their surgical and anesthesia teams.

Step 1. Screen all breast cancer surgery patients for preoperative depressive symptoms using a validated tool — the PHQ-9 or MADRS — at least 24–48 hours before the scheduled procedure. Identify patients scoring above the clinical threshold (PHQ-9 ≥ 5 or MADRS ≥ 10).

Step 2. If the patient has preexisting depressive symptoms and no contraindications to ketamine-class agents (uncontrolled hypertension, active psychosis, known hypersensitivity), discuss the option of intraoperative esketamine with the anesthesia team.

Step 3. Administer esketamine 0.2–0.25 mg/kg IV at anesthesia induction. Based on the Zhu et al. protocol, infuse over the first 40 minutes of anesthesia. Alternatively, following the BMC Psychiatry protocol, continue with a maintenance infusion of 0.1 mg/kg/h until surgery concludes ^[3][4].

Step 4. Monitor hemodynamic parameters closely during infusion. Esketamine can elevate blood pressure and heart rate transiently. Have standard antihypertensive agents available.

Step 5. Assess depressive symptoms postoperatively using the same validated scale at day 1, day 3, day 7, and day 30. The Zhu et al. trial also assessed at week 12, which I'd recommend for longitudinal tracking.

Step 6. For institutions with access to resting-state fMRI, consider baseline neuroimaging as a potential predictor of esketamine response. While not yet clinically actionable at scale, baseline functional connectivity metrics — particularly characteristic path length and connectivity involving the left precuneus and putamen — showed predictive value in the Zhu et al. dataset ^[3].

Step 7. Document outcomes and contribute to institutional registries. The evidence base needs larger, multicenter trials before this becomes protocol. Every case documented moves the needle.

What is esketamine, and how does it differ from ketamine?#

Esketamine is the S-enantiomer of ketamine, meaning it's one of the two mirror-image molecules that make up racemic ketamine. It has roughly twice the binding affinity for NMDA receptors compared to the R-enantiomer, which translates to needing lower doses for equivalent effect. The FDA-approved nasal spray (Spravato) uses esketamine specifically, while IV ketamine clinics typically use the racemic mixture.

How quickly does intraoperative esketamine reduce depressive symptoms?#

In the Zhu et al. trial, measurable changes in brain functional connectivity and depressive symptoms appeared as early as postoperative day 1 ^[3]. The larger BMC Psychiatry trial showed significant PHQ-9 improvements at postoperative day 7, sustained through day 30 ^[4]. This is dramatically faster than the 2–6 week onset typical of SSRIs.

Who is a good candidate for perioperative esketamine?#

Based on current evidence, breast cancer patients with preoperative depressive symptoms (screened via PHQ-9 or MADRS) who are undergoing elective surgery appear to benefit most. Patients with uncontrolled hypertension, active psychosis, or history of ketamine misuse should be excluded. The Zhu et al. data also suggests that baseline brain network architecture may eventually help identify optimal responders, though this requires validation.

Why does the left inferior frontal gyrus matter for depression?#

The left IFG opercular part is involved in cognitive control, emotional reappraisal, and regulation of negative affect. Increased connectivity of this region suggests enhanced capacity to modulate depressive thought patterns. I'd frame it as the brain's ability to interrupt rumination — it's not about being happy, it's about having more functional options when confronted with distress.

What are the risks of intraoperative esketamine?#

The most commonly reported adverse effects include transient increases in blood pressure and heart rate, nausea, and — at higher doses — dissociative symptoms. At the subanesthetic doses used in these trials (0.2–0.25 mg/kg), serious adverse events appear rare, but we need larger safety datasets. Honestly, the safety profile at these doses seems manageable, but the honest answer is long-term data beyond 12 weeks is sparse.

Verdict#

Score: 7/10

The Zhu et al. trial is mechanistically elegant — pinpointing a specific brain region whose connectivity change correlates with antidepressant response, and demonstrating that baseline network architecture may predict who benefits. That's the kind of precision neuroscience that could eventually inform clinical decision-making. The converging evidence from a larger 120-patient RCT and molecular work on TREK-1 channels adds substance.

But I can't ignore the core limitation: n = 35. The predictive biomarker analysis, however sophisticated the graph theory, is exploratory at this sample size. I'd want to see multicenter replication with at least 100 patients per arm before changing any perioperative protocol. The TREK-1 mechanism data is preclinical — rat neurons, not human brains. And the 12-week follow-up, while better than most ketamine studies, still leaves the durability question open.

What I do find compelling: the convergence of timing, mechanism, and prediction. If validated, this could shift perioperative psychiatric care from reactive to proactive. That's worth paying attention to.